Every Form 4 that RxSight, Inc. (RXST) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow RXST and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RXST filings page.
RxSight, Inc. (RXST) reported that Chief Business Development Officer Eric Weinberg exercised stock options for 35,168 shares of common stock on September 15, 2026 at an exercise price of $4.34 per share, increasing his directly held common stock to 235,516 shares.
He also is reported as having indirect ownership of 299,978 shares of common stock through the EJW Living Trust, where he serves as trustee, and 925 shares held by his spouse. The options exercised were fully vested and exercisable, and no Rule 10b5-1 trading plan is reported for these transactions.
RxSight, Inc. (RXST) reported that Chief Financial Officer Mark Wilterding participated in an option exchange on September 5, 2026. An existing stock option for 258,770 shares with a $10.09 exercise price was returned to the issuer and replaced on a 1:1 basis with a new option for 258,770 shares at a $6.375 exercise price. The new option vests in equal monthly installments over 24 months starting February 28, 2027, contingent on continued service.
RxSight, Inc. reported an option exchange for Chief Business Development Officer Eric Weinberg on September 5, 2026. Several outstanding stock options were returned to the company, including grants for 87,437, 95,000, 92,200, 50,000, and 125,000 shares with exercise prices ranging from $14.95 to $56.07 per share. In connection with the issuer’s option exchange program, these were replaced with new options for 65,742, 82,608, 59,483, 32,258, and 93,984 shares at a post‑exchange exercise price of $6.375 per share, subject to time‑based vesting conditions through 2027. No Rule 10b5‑1 trading plan is reported, and all positions are held directly.
RxSight, Inc. reported that Chief Medical Officer Ronald M. Kurtz, MD adjusted his equity awards on September 5, 2026 in connection with an option exchange program. He returned four outstanding stock option grants to the company and received four replacement options with a lower exercise price of $6.375 per share, each with specified vesting schedules tied to continued service.
RxSight, Inc. (RXST) reported that Chief Operating Officer Ilya Goldshleger participated in an employee option exchange program on September 5, 2026. Several existing stock options with higher exercise prices, including options exercisable at $16.00, $14.95, $28.21, $46.24, and $56.07 per share, were disposed of to the issuer and replaced on specified exchange ratios with new options.
The new stock options carry a post-exchange exercise price of $6.375 per share and various vesting schedules tied to continued service under the 2021 Equity Incentive Plan. Some new grants vest monthly over 48 months from vesting commencement dates in 2023–2025, while others vest in 2027 on a 25%/75% schedule with additional monthly vesting components.
RxSight, Inc. (RXST) reported that Chief Medical Officer Ronald M. Kurtz, MD had 13,425 Restricted Stock Units vest on August 31, 2026, converting into 13,425 shares of common stock. On the same date, he continued to hold 67,120 RSUs directly. On September 2, 2026, 5,100 common shares were sold at $6.96 per share to satisfy tax withholding obligations related to this RSU vesting, which the company notes did not represent a discretionary sale. Separately, 764,610 common shares are held indirectly through Cricklewood LP, an entity over which Dr. Kurtz shares voting and investment control with his spouse.
RxSight, Inc. (RXST) reported that Chief Financial Officer Mark Wilterding had Restricted Stock Units vest and related share movements in late August 2026. On August 31, 2026, 20,441 RSUs, each representing a contingent right to one share of common stock, converted into 20,441 common shares, leaving him with 122,646 shares held directly after this derivative transaction. On September 2, 2026, he sold 7,765 common shares at $6.96 per share to cover tax withholding obligations arising from the RSU vesting, which the company states did not represent a discretionary sale. No Rule 10b5-1 trading plan is reported.
RxSight, Inc. (RXST) Chief Operating Officer Ilya Goldshleger reported transactions involving Common Stock and Restricted Stock Units. On August 31, 2026, RSUs representing 5,370 shares converted into Common Stock, resulting in 26,848 shares held directly. On September 2, 2026, 2,041 shares of Common Stock were sold at $6.96 per share to cover tax withholding obligations related to RSU vesting, which the company states was not a discretionary sale. Goldshleger also reports indirect ownership of 1,372 shares held by his spouse. No transactions are reported under a Rule 10b5-1 trading plan.
RxSight, Inc. (RXST) reported that Chief Business Development Officer Eric Weinberg had restricted stock units convert into 5,370 shares of Common Stock on August 31, 2026, with no exercise price, and that 2,041 shares of Common Stock were sold on September 2, 2026 at $6.96 per share. According to the company, the 2,041 shares sold "represent the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale" by Weinberg, and no Rule 10b5-1 trading plan is reported. After these events, Weinberg continues to hold Common Stock indirectly through the EJW Living Trust and his spouse, and retains a significant RSU position scheduled to vest in six installments between August 31, 2026 and February 28, 2029, subject to his continued service.
RxSight, Inc. granted President and CEO Aziz Mottiwala 2,312,138 restricted stock units, each representing a contingent right to one share of Common Stock, and stock options for 571,286 shares at an exercise price of $5.19 per share. The RSUs and options vest over multi-year schedules contingent on continued service, with resulting direct holdings equal to the granted amounts.
Warner Robert Keith reported acquisition or exercise transactions in this Form 4 filing.
RxSight, Inc. director Robert Keith Warner received an equity award of 37,037 restricted stock units (RSUs) of common stock as compensation. Each RSU represents one share of RxSight common stock, bringing his direct holdings to 78,076 shares following the grant.
The RSUs will vest in full if he continues as an Outside Director until the earlier of the one-year anniversary of the June 17, 2026 grant date or the next annual meeting of stockholders after that date. This is a non-cash award rather than an open-market share purchase.
PALMISANO ROBERT J reported acquisition or exercise transactions in this Form 4 filing.
RxSight, Inc. director Robert J. Palmisano reported receiving a grant of 37,037 restricted stock units (RSUs) of Common Stock as compensation. Each RSU represents the right to receive one share of RxSight common stock. Following this award, he holds 78,076 shares directly.
The RSUs will fully vest in a single tranche if he continues as an Outside Director through the vesting date. Vesting occurs on the earlier of the one-year anniversary of the June 17, 2026 grant date or the next annual meeting of stockholders after that grant date.
Maniar Shweta reported acquisition or exercise transactions in this Form 4 filing.
RxSight, Inc. director Shweta Maniar received a grant of 37,037 restricted stock units (RSUs) of Common Stock. The award was reported at a price of $0.00 per share, consistent with a compensation grant rather than a market purchase.
Each RSU represents the right to receive one share of RxSight Common Stock. The RSUs will vest in full if Maniar continues as an Outside Director until the earlier of the one-year anniversary of the June 17, 2026 grant date or the next annual meeting of stockholders following that date. After this award, Maniar directly holds 55,172 shares.
Fountain Tamara reported acquisition or exercise transactions in this Form 4 filing.
RxSight, Inc. director Tamara Fountain received a grant of 37,037 shares of Common Stock in the form of restricted stock units (RSUs). This is a compensation-related award at no cash cost to her, not an open-market purchase.
Each RSU represents one share of RxSight common stock. All RSUs will vest together if she continues as an Outside Director until the earlier of the first anniversary of the June 17, 2026 grant date or the next annual stockholder meeting. After this award, she directly holds 72,582 shares.
LINK WILLIAM J PHD reported acquisition or exercise transactions in this Form 4 filing.
RxSight, Inc. director William J. Link received an equity grant of 37,037 shares of Common Stock as a stock award, with no cash paid per share. After this award, his directly held Common Stock position reported in this filing totals 74,892 shares.
The award is structured as restricted stock units, each representing a contingent right to one share of RxSight Common Stock. All RSUs vest 100% on the earlier of the one-year anniversary of the June 17, 2026 grant date or the next annual stockholder meeting, subject to his continuing as an Outside Director. Separately, 21,248 shares are held indirectly through Link Family Enterprise, L.P., where he may be deemed to share voting and investment power but disclaims beneficial ownership beyond his pecuniary interest.
Corley Jesse Anderson reported acquisition or exercise transactions in this Form 4 filing.
RxSight, Inc. director Corley Jesse Anderson received a grant of 37,037 restricted stock units (RSUs) of Common Stock as compensation. Each RSU represents one share and was granted at $0.00 per share. Subject to his continuing service as an Outside Director, all RSUs vest on the earlier of the one-year anniversary of the June 17, 2026 grant date or the next annual stockholder meeting. Following the grant, he holds 86,227 shares directly and additional indirect positions through the Andy Corley Living Trust, The Corley Foundation, the Juana McKay Living Trust, and shares held by his spouse.
COHEN RAYMOND W reported acquisition or exercise transactions in this Form 4 filing.
RxSight, Inc. director Raymond W. Cohen received a grant of 30,864 restricted stock units (RSUs), each representing one share of common stock. The RSUs vest 100% on the earlier of the one-year anniversary of the June 17, 2026 grant date or the next annual stockholder meeting, subject to his continued service as an Outside Director. Following this equity award, Cohen holds 66,532 shares/RSUs of RxSight common stock directly.
Tammenoms Bakker Juliet reported acquisition or exercise transactions in this Form 4 filing.
RxSight, Inc. board member Juliet Tammenoms Bakker reported an equity compensation grant in the form of restricted stock units. She received 37,037 RSUs, each representing one share of RxSight common stock, at a price of $0.00 per share, increasing her direct holdings to 85,183 shares.
The RSUs vest 100% on the earlier of the one-year anniversary of the June 17, 2026 grant date or the next annual stockholder meeting, subject to her continued service as an Outside Director. She also has 1,548 shares held indirectly in a trust, where she may share voting and investment power but disclaims beneficial ownership beyond her economic interest.
Andrews Julie reported acquisition or exercise transactions in this Form 4 filing.
RxSight, Inc. director Julie Andrews received a grant of 37,037 restricted stock units, each representing a right to one share of common stock at no cost. The RSUs vest in full on the earlier of the one-year anniversary of the June 17, 2026 grant date or the next annual stockholder meeting, contingent on her continuing as an Outside Director. Following this award, she holds 78,076 shares directly.
RxSight, Inc. Chief Operating Officer Ilya Goldshleger exercised stock options to acquire 12,489 shares of common stock at $4.13 per share. Following the transactions, he holds 78,180 shares directly and 1,372 shares indirectly through his spouse, indicating a routine compensation-related equity exercise with no open-market buying or selling disclosed.
RxSight, Inc. Chief Financial Officer Mark Wilterding reported equity award activity involving restricted stock units and related common stock. On February 28, 2026, 20,441 restricted stock units were exercised into 20,441 shares of common stock at a price of $0.00 per share. To cover tax obligations on this vesting event, 8,068 shares of common stock were disposed of at $7.61 per share through a tax-withholding arrangement rather than an open-market sale. Footnotes state that one eighth of the RSU award vested on February 28, 2026, with additional one-eighth installments scheduled to vest every six months through the end of a four-year period, subject to continued service.
RxSight, Inc. Chief Customer Officer Scott Gaines reported multiple equity transactions. On February 27, 2026, he received a grant of 32,218 restricted stock units (RSUs), each representing one share of common stock, subject to multi‑year service-based vesting. On February 28, 2026, several RSU awards vested and were exercised, resulting in the acquisition of 6,261 shares of common stock at a stated price of $0.00 per share. On the same date, 2,580 shares of common stock were disposed of at $7.61 per share to cover tax withholding obligations. After these transactions, Gaines directly owned 14,848 shares of RxSight common stock.
Goldshleger Ilya reported acquisition or exercise transactions in this Form 4 filing.
RxSight, Inc. reported that Chief Operating Officer Ilya Goldshleger received a grant of 32,218 restricted stock units on February 27, 2026. Each RSU represents a right to one share of common stock. The award vests in six equal installments on trading days on or after August 31, 2026, February 28, 2027, August 31, 2027, February 28, 2028, August 31, 2028, and February 28, 2029, if he continues as a service provider.
Weinberg Eric reported acquisition or exercise transactions in this Form 4 filing.
RxSight, Inc. reported that officer Eric Weinberg received a grant of 32,218 restricted stock units (RSUs), each representing the right to receive one share of common stock. The award vests in six equal installments on trading days on or after August 31, 2026, February 28, 2027, August 31, 2027, February 28, 2028, August 31, 2028, and February 28, 2029, subject to his continued service.
Kurtz Ronald M MD reported acquisition or exercise transactions in this Form 4 filing.
RxSight, Inc. President & CEO Ronald M. Kurtz received a grant of 80,545 restricted stock units. Each RSU represents a contingent right to receive one share of RxSight common stock.
The award vests in six equal installments, with one-sixth vesting on the first trading day on or after each of August 31, 2026, February 28, 2027, August 31, 2027, February 28, 2028, August 31, 2028 and February 28, 2029, as long as he continues as a service provider under the company’s 2021 Equity Incentive Plan.
RxSight, Inc. reported new equity awards to Chief Financial Officer Mark Wilterding. On January 12, 2026, he received a stock option covering 258,770 shares of common stock at an exercise price of $10.09 per share. Twenty five percent of this option vests on January 11, 2027, with the remainder vesting in equal monthly installments over the following three years, contingent on continued service.
He also received 163,528 restricted stock units, each representing one share of common stock. One eighth of the RSUs will vest on February 28, 2026, with additional one-eighth portions vesting every six months on the last day of February and August over a four-year period, also subject to his continued service.
Insider purchases reported for RxSight, Inc. (RXST). On 09/25/2025 Co-President and Chief Operating Officer Ilya Goldshleger acquired 15,096 and 8,349 shares of common stock at $4.34 and $4.13 per share respectively, increasing his direct holdings to 65,691 shares. Separate stock option exercises or grants totaling 23,445 options at $4.34 and $4.13 were also reported. Holdings include 1,372 shares held indirectly by spouse.